专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5260941A Digital radio telephone system 失效
标题翻译：数字无线电话系统
公开(公告)号：US5260941A
公开(公告)日：1993-11-09
申请号：US890720
申请日：1992-05-29
申请人： Ronald Wilder , Gregory Pierce , Richard C. Frey , Whitney E. Childs-Goodrich , David L. Needle
发明人： Ronald Wilder , Gregory Pierce , Richard C. Frey , Whitney E. Childs-Goodrich , David L. Needle
IPC分类号： H04W84/16 , H04L5/22
CPC分类号： H04W84/16
摘要： The telephone system of the present invention is realized by a unique dynamic time slice architecture which allows for up to 480 transfers of data. A dual port RAM is utilized in which are stored two pages of data, containing time slice information identifying the sending and receiving devices for each time slice slot within the frame. The time slice configuration can be easily modified to accommodate a change in the current system configuration, for example, a handset connecting or disconnecting from a central office line, or the initiation of a conference call. The time slice configuration is modified by updating the second page and swapping the two pages at the beginning of the next frame so that the time slice controller accesses the second page and the configurations specified therein. Thus the system can be updated and controlled in real time with no delays to the users of the telephone system. The telephone system of the present invention further provides a dynamic conferencing capability which can accommodate a large number of users with no additional circuitry and little additional system overhead. The conferencing circuit linearly combines digitized audio data received from different sources over successive time slice slots in a single frame on a real time basis wherein parties can be added or removed simply by adding or removing the connections to the time slice slots.
摘要翻译：本发明的电话系统通过独特的动态时间片结构来实现，其允许多达480个数据传输。使用双端口RAM，其中存储两页数据，其中包含标识帧内每个时间片时隙的发送和接收设备的时间片信息。可以容易地修改时间片配置以适应当前系统配置的变化，例如，连接或断开与中心局线路的手机或者召开电话会议。通过更新第二页并在下一帧的开头交换两个页面来修改时间片配置，使得时间片控制器访问第二页以及其中指定的配置。因此，可以实时更新和控制系统，而不会延迟电话系统的用户。本发明的电话系统还提供动态会议能力，其可以容纳大量用户，没有额外的电路和少量额外的系统开销。会议电路在实时基础上将单个帧中连续时间片时隙上的从不同来源接收的数字化音频数据线性组合，其中可以通过添加或去除与时间片时隙的连接来简单地添加或删除各方。

2. 发明申请

US20070077246A1 Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity 有权
标题翻译：使用免疫抑制性单克隆抗体治疗自身免疫性疾病的方法，毒性降低
公开(公告)号：US20070077246A1
公开(公告)日：2007-04-05
申请号：US11485557
申请日：2006-07-11
申请人： Scott Koenig , Ronald Wilder , Ezio Bonvini , Leslie Johnson
发明人： Scott Koenig , Ronald Wilder , Ezio Bonvini , Leslie Johnson
IPC分类号： A61K39/395 , A61K38/28 , C12P21/06 , C07K16/28 , A61K38/22 , C12N5/06
CPC分类号： C07K16/2809 , A61K38/28 , A61K2039/505 , C07K2317/24 , C07K2317/524 , C07K2317/53 , C07K2317/71 , A61K2300/00
摘要： The present invention provides methods of treating, preventing or ameliorating the symptoms of T cell-mediated immunological diseases, particularly autoimmune diseases, through the use of anti-CD3 antibodies. In particular, the methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the invention provides for modification of the anti-CD3 antibodies such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-CD3 antibodies.
摘要翻译：本发明提供了通过使用抗CD3抗体来治疗，预防或改善T细胞介导的免疫疾病，特别是自身免疫性疾病的症状的方法。特别地，本发明的方法提供了特异性结合人CD3复合物内的ε亚基的抗体的施用。这种抗体调节T细胞受体/同种异体抗原相互作用，因此调节与自身免疫疾病相关的T细胞介导的细胞毒性。另外，本发明提供抗CD3抗体的修饰，使得与未修饰的抗CD3抗体相比，它们表现出降低或消除的效应子功能和T细胞活化。

3. 发明授权

US08663634B2 Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity 有权
标题翻译：使用免疫抑制性单克隆抗体治疗自身免疫性疾病的方法，毒性降低
公开(公告)号：US08663634B2
公开(公告)日：2014-03-04
申请号：US11485557
申请日：2006-07-11
申请人： Scott Koenig , Ronald Wilder , Ezio Bonvini , Leslie S. Johnson
发明人： Scott Koenig , Ronald Wilder , Ezio Bonvini , Leslie S. Johnson
IPC分类号： A61K39/395 , A61K39/40 , C07K16/00
CPC分类号： C07K16/2809 , A61K38/28 , A61K2039/505 , C07K2317/24 , C07K2317/524 , C07K2317/53 , C07K2317/71 , A61K2300/00
摘要： The present invention provides methods of treating, preventing or ameliorating the symptoms of T cell-mediated immunological diseases, particularly autoimmune diseases, through the use of anti-CD3 antibodies. In particular, the methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the invention provides for modification of the anti-CD3 antibodies such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-CD3 antibodies.
摘要翻译：本发明提供了通过使用抗CD3抗体来治疗，预防或改善T细胞介导的免疫疾病，特别是自身免疫性疾病的症状的方法。特别地，本发明的方法提供了特异性结合人CD3复合物内的ε亚基的抗体的施用。这种抗体调节T细胞受体/同种异体抗原相互作用，因此调节与自身免疫疾病相关的T细胞介导的细胞毒性。另外，本发明提供抗CD3抗体的修饰，使得与未修饰的抗CD3抗体相比，它们表现出降低或消除的效应子功能和T细胞活化。

4. 发明申请

US20080095766A1 Methods for the Treatment of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies with Reduced Toxicity 有权
标题翻译：使用具有降低毒性的免疫抑制性单克隆抗体治疗自身免疫性疾病的方法
公开(公告)号：US20080095766A1
公开(公告)日：2008-04-24
申请号：US11763434
申请日：2007-06-14
申请人： Scott Koenig , Ronald Wilder , Ezio Bonvini , Leslie Johnson , Stanley Pillemer
发明人： Scott Koenig , Ronald Wilder , Ezio Bonvini , Leslie Johnson , Stanley Pillemer
IPC分类号： A61K39/395 , A61P1/00 , A61P17/06 , A61P19/02 , A61P25/00 , A61P3/10 , A61P35/00 , A61P37/06
CPC分类号： C07K16/2809 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K2317/24 , C07K2317/41 , C07K2317/71
摘要： The present invention provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of T cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes (i.e. type 1 diabetes or insulin-dependent diabetes mellitus (IDDM)) and multiple sclerosis) through the use of anti-human CD3 antibodies. The antibodies of the invention of the invention are preferably used in low dose dosing regimens, chronic dosing regimens or regimens that involve redosing after a certain period of time. The methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the methods of the invention provide for use of anti-human CD3 antibodies modified such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies.
摘要翻译：本发明提供治疗，预防，减缓T细胞介导的免疫疾病，特别是自身免疫疾病（例如，自身免疫性糖尿病（即1型糖尿病或胰岛素依赖性糖尿病（IDDM））的症状的进展或改善的方法，以及多发性硬化）通过使用抗人CD3抗体。本发明的本发明的抗体优选用于低剂量给药方案，慢性给药方案或方案，其涉及经过一段时间后的再次给药。本发明的方法提供了特异性结合人CD3复合物内的ε亚基的抗体的施用。这种抗体调节T细胞受体/同种异体抗原相互作用，因此调节与自身免疫疾病相关的T细胞介导的细胞毒性。此外，本发明的方法提供使用经修饰的抗人CD3抗体，使得与未修饰的抗人CD3抗体相比，它们表现出降低或消除的效应子功能和T细胞活化。

5. 发明申请

US20090053234A1 Methods of Preventing or Treating Inflammatory or Autoimmune Disorders by Administering Integrin ALPHAVBETA3 Antogonists in Combination with other Prophylactic or Therapeutic Agents 审中-公开
标题翻译：通过管理整合素ALPHAVBETA3 Antogonists与其他预防或治疗剂组合预防或治疗炎症或自身免疫性疾病的方法
公开(公告)号：US20090053234A1
公开(公告)日：2009-02-26
申请号：US12048738
申请日：2008-03-14
申请人： Christine Dingivan , Ronald Wilder
发明人： Christine Dingivan , Ronald Wilder
IPC分类号： A61K39/395 , A61K31/519 , A61K31/42 , A61K31/675 , A61K38/13 , A61K31/436 , A61K38/00 , A61K31/60 , A61K31/192 , A61K31/196 , A61K31/122
CPC分类号： C07K16/2848 , A61K39/39541 , A61K2039/505 , A61K2039/545 , C07K16/241 , C07K16/2806 , C07K2317/24 , A61K2300/00
摘要： The present invention provides to methods of preventing, treating or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder utilizing combinatorial therapy. In particular, the present invention provides methods of preventing, treating, or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder comprising administering to a subject in need thereof one or more integrin αVβ3 antagonists and at least one other prophylactic or therapeutic agent. The present invention also provides compositions and articles of manufacture for use in preventing, treating or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder.
摘要翻译：本发明提供了使用组合疗法预防，治疗或改善与自身免疫性或炎症性疾病相关的一种或多种症状的方法。特别地，本发明提供了预防，治疗或改善与自身免疫性或炎症性疾病相关的一种或多种症状的方法，包括向有需要的受试者施用一种或多种整合素αVβ3拮抗剂和至少一种其它预防或治疗剂。本发明还提供用于预防，治疗或改善与自身免疫性或炎症性疾病相关的一种或多种症状的组合物和制品。

6. 发明申请

US20050084489A1 Methods of preventing or treating disorders by administering and integrin alphanubeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate 审中-公开
公开(公告)号：US20050084489A1
公开(公告)日：2005-04-21
申请号：US10379145
申请日：2003-03-04
申请人： Ronald Wilder , Su-Yau Mao
发明人： Ronald Wilder , Su-Yau Mao
IPC分类号： A61K45/00 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/404 , A61K31/4418 , A61K31/505 , A61K31/565 , A61K31/59 , A61K31/663 , A61K31/675 , A61K38/23 , A61K39/395 , A61K45/06 , A61K47/48 , A61P1/00 , A61P1/02 , A61P1/04 , A61P3/10 , A61P9/08 , A61P9/10 , A61P11/00 , A61P13/08 , A61P15/00 , A61P17/00 , A61P19/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07K16/28 , G01N33/574 , A61K31/66
CPC分类号： A61K31/565 , A61K31/59 , A61K31/663 , A61K38/23 , A61K39/39541 , A61K45/06 , A61K47/64 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K16/2848 , G01N33/574 , A61K2300/00
摘要： The present invention provides methods of preventing, treating, managing or ameliorating disorders utilizing an integrin αvβ3 antagonist in combination with an HMG-CoA reductase inhibitor and/or a bisphosphonate. The present invention also encompasses methods of preventing, treating, managing or ameliorating disorders utilizing an integrin αvβ3 antagonist in combination with an HMG-CoA reductase inhibitor and/or a bisphophonate, in further combination with another therapy (e.g., another prophylactic or therapeutic agent or treatment) which is not an integrin αvβ3 antagonist, an HMG-CoA reductase inhibitor, or a bisphosphonate. In particular, the present invention provides methods of preventing, treating, managing or ameliorating inflammatory diseases, autoimmune disorders, disorders associated with aberrant expression and/or activity of integrin αvβ3, disorders associated with abnormal bone metabolism, disorders associated with aberrant angiogenesis and cancers, or conditions associated therewith, utilizing an antibody that immunospecifically binds to integrin αvβ3 (e.g., VITAXIN®) in combination with an HMG-CoA reductase inhibitor and/or bisphosphonate, and optionally in combination with another therapy (e.g., another prophylactic or therapeutic agent or treatment) which is not an integrin αvβ3 antagonist, an HMG-CoA reductase inhibitor, or a bisphosphonate. The present also invention encompasses compositions and articles of manufacture for use in preventing, treating, managing or ameliorating inflammatory diseases, autoimmune disorders, disorders associated with aberrant expression and/or activity of integrin αvβ3, disorders associated with abnormal bone metabolism, disorders associated with aberrant angiogenesis and cancers, or conditions associated therewith.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式